Table 2.
Baseline clinical and immunological status of Children on ART at Felege Hiwot referral hospital, January 1st, 2006 - March 31st, 2011
| Variable | Frequency | Percent (%) | |
|---|---|---|---|
|
ART eligibility criteria |
|
|
|
| WHO clinical stage |
|
9 |
1.6 |
| Immunological/CD4Count |
|
35 |
6.4 |
| Both clinical and immunologic |
|
505 |
92.0 |
|
Type of drug at initiation of therapy |
|
|
|
| 4a(d4T-3TC-NVP) |
|
208 |
37.9 |
| 4b(d4T-3TC-EFV) |
|
37 |
6.7 |
| 4c(AZT-3TC-NVP) |
|
258 |
47.0 |
| 4d(AZT-3TC-EFV) |
|
43 |
7.8 |
| Kaletra based |
|
3 |
0.6 |
|
Regimen change during follow up |
|
|
|
| Yes |
|
68 |
12.5 |
| No |
|
475 |
87.5 |
|
Absolute CD4 count |
|
|
|
| CD4 count below the threshold |
|
289 |
52.6 |
| CD4 count above the threshold |
|
260 |
47.4 |
|
Developmental History |
|
|
|
| Appropriate |
|
531 |
96.7 |
| Delayed |
|
9 |
1.6 |
| Regressing |
|
9 |
1.6 |
|
Cotrimoxazole preventive therapy |
|
|
|
| Yes |
|
287 |
52.3 |
| No |
|
262 |
47.7 |
|
Nutritional status |
|
|
|
| Underweight |
|
453 |
82.5 |
| Normal |
|
92 |
16.8 |
| Overweight |
|
4 |
0.7 |
|
WHO clinical staging |
|
|
|
| I |
|
45 |
8.2 |
| II |
|
128 |
23.3 |
| III |
|
317 |
57.7 |
| IV |
|
59 |
10.7 |
|
Haemoglobin(520) |
|
|
|
| <10gm/dl |
|
103 |
19.8 |
| ≥10gm/dl |
|
417 |
80.2 |
|
3rdmonth ART drug adherence (497) |
|
|
|
| Good |
|
491 |
98.8 |
| Fair |
|
3 |
0.6 |
| Poor |
|
3 |
0.6 |
|
OIs during follow up |
|
|
|
| Yes |
|
165 |
30.1 |
| No |
|
384 |
69.9 |
|
Side effect during follow up(526) |
|
|
|
| Yes |
|
49 |
8.9 |
| No | 477 | 86.9 | |